BS_GJNCYABP
ATRT
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ATRT
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ATRT
- overall_survival_months
- 23.19316688567674
- age_years
- 15.584
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.695
- INTERFERON_GAMMA_RESPONSE+0.669
- ALLOGRAFT_REJECTION+0.657
- IL6_JAK_STAT3_SIGNALING+0.563
- INFLAMMATORY_RESPONSE+0.521
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.471
- TNFA_SIGNALING_VIA_NFKB+0.470
- MYC_TARGETS_V1+0.446
- IL2_STAT5_SIGNALING+0.424
- E2F_TARGETS+0.409
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.289
- MYOGENESIS-0.260
- UV_RESPONSE_DN-0.230
- MITOTIC_SPINDLE-0.229
- WNT_BETA_CATENIN_SIGNALING-0.178
- NOTCH_SIGNALING-0.135
- SPERMATOGENESIS-0.100
- ANGIOGENESIS-0.075
- PANCREAS_BETA_CELLS-0.072
- APICAL_JUNCTION-0.042
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GC-A6I1-01A-12R-A31N-07 | — | — | 0.920 |
| 2 | SRR6013516 | — | cohortA1 | 0.915 |
| 3 | BS_8GW1TMV2 | Med | Medulloblastoma | 0.910 |
| 4 | 8f1213be-da41-4cd6-97b2-f9fce1ea00ff | — | — | 0.907 |
| 5 | 1e0f16e6-de1c-4d1e-b1f6-5fabbea1591b | — | — | 0.898 |
| 6 | SRR934888 | — | — | 0.896 |
| 7 | B8AED170-C88C-4A86-8377-93B5D14AB334 | — | — | 0.895 |
| 8 | TCGA-DK-A3WW-01A-22R-A23N-07 | — | — | 0.892 |
| 9 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.891 |
| 10 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.695 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.669 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.657 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.563 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.521 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.471 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.446 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.424 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.409 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.404 | Idelalisib | — uncovered |
| COMPLEMENT | 0.391 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.384 | Inavolisib | — uncovered |
| APOPTOSIS | 0.360 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.334 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.324 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.322 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.288 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.281 | Inavolisib | — uncovered |